Futurecast to commercialise semi-quantitative CE-certified rougeN™ COVID-19 Vaccine Immune Response Test Kit following strategic partnership with US-based RougeN Diagnostics Inc.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
Futurecast Ltd, an end-to-end screening solutions at Point of Need(PON) provider, has entered into a strategic distribution agreement with US-based RougeN Diagnostics Inc. to commercialise its CE-certified rougeN™ Immune Response Test Kit. The rougeN™ test kit has been developed to measure the concentration of neutralising antibodies to COVID-19 or the level of antibodies to the receptor-binding domain of the spike protein, which is a major component of the COVID-19 vaccine. The test offers a non-invasive solution to neutralising antibody testing and provides a reliable (98.47% accuracy) semi-quantitative result within 15 minutes. It is simple and cost-effective.
can be used to monitor IgG neutralising antibody responses post-infection or vaccination. It gives an indication on immunity status, helping individuals to make more informed decisions about their social interactions, and contributing to maintain public safety. Futurecast will make rougeN™ available to client labs as well as distribution partners in Europe, Middle East & Africa.
“Large-scale immune response testing helps understand the dynamics of the pandemic, and evolve more effective responses, particularly in the context of the proliferation of variants. Among other benefits, monitoring antibody levels helps determine vaccine durability, adapt vaccination strategies, and allows individuals to enjoy the benefits of increased social activity as social restrictions ease. Those who are not immune may opt to be more cautious, or be allowed an additional vaccine shot, subject to local regulations,” said Cecile Goulet, Chief Clinical Innovation Officer at Futurecast.
Futurecast Ltd, an end-to-end screening solutions at Point of Need(PON) provider, has entered into a strategic distribution agreement with US-based RougeN Diagnostics Inc. to commercialise its CE-certified rougeN™ Immune Response Test Kit. The rougeN™ test kit has been developed to measure the concentration of neutralising antibodies to COVID-19 or the level of antibodies to the receptor-binding domain of the spike protein, which is a major component of the COVID-19 vaccine. The test offers a non-invasive solution to neutralising antibody testing and provides a reliable (98.47% accuracy) semi-quantitative result within 15 minutes. It is simple and cost-effective.
can be used to monitor IgG neutralising antibody responses post-infection or vaccination. It gives an indication on immunity status, helping individuals to make more informed decisions about their social interactions, and contributing to maintain public safety. Futurecast will make rougeN™ available to client labs as well as distribution partners in Europe, Middle East & Africa.
“Large-scale immune response testing helps understand the dynamics of the pandemic, and evolve more effective responses, particularly in the context of the proliferation of variants. Among other benefits, monitoring antibody levels helps determine vaccine durability, adapt vaccination strategies, and allows individuals to enjoy the benefits of increased social activity as social restrictions ease. Those who are not immune may opt to be more cautious, or be allowed an additional vaccine shot, subject to local regulations,” said Cecile Goulet, Chief Clinical Innovation Officer at Futurecast.
Yves Alavo, Founder & CEO of Futurecast adds: “This strategic partnership to lead the rollout of the rougeN™ test across these markets fully supports our vision to power health surveillance by making the most effective rapid screening innovations available to healthcare providers and individuals alike. While the rougeN™ test is already CE-certified it is currently under review by UK Department of Health & Social Care”.
About Futurecast Ltd.
We are accelerating the advent of a decentralised and democratised healthcare ecosystem by simplifying access to innovation in care and empowering healthcare and non-healthcare operators. As an unconventional care company, our vision is to become the largest contributor to the state of preparedness of the world against health threats.
About RougeN Diagnostics Inc.
We are an innovative, USA-based biotech company specialised in rapid tests for emerging infectious diseases - and sold worldwide. Through innovative research and collaboration with public health institutions, governments and medical researchers, RougeN Diagnostics provides mission-critical testing for patients and healthcare providers. Our lab partner operates in a fully HIPAA compliant environment.
It is clear to most global and local authorities that a return to a normal society now requires a robust and secure health management system in the form of a digital health pass. The race to build and implement these systems has revealed a host of dilemmas and disparities that have left governments and end-users struggling to find a successful balance of trust, ease-of-use and common agreement and understanding.
The seismic changes created by the Covid-19 pandemic have taught us many valuable lessons, especially when it comes to recognizing the deficiencies in global screening and testing systems. How we recognize those vulnerabilities and collaborate to mitigate them, is now key to the creation of robust new systems designed to cope with the demands of a post-Covid world.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
Futurecast Ltd, an end-to-end screening solutions at Point of Need(PON) provider, has entered into a strategic distribution agreement with US-based RougeN Diagnostics Inc. to commercialise its CE-certified rougeN™ Immune Response Test Kit. The rougeN™ test kit has been developed to measure the concentration of neutralising antibodies to COVID-19 or the level of antibodies to the receptor-binding domain of the spike protein, which is a major component of the COVID-19 vaccine. The test offers a non-invasive solution to neutralising antibody testing and provides a reliable (98.47% accuracy) semi-quantitative result within 15 minutes. It is simple and cost-effective.
can be used to monitor IgG neutralising antibody responses post-infection or vaccination. It gives an indication on immunity status, helping individuals to make more informed decisions about their social interactions, and contributing to maintain public safety. Futurecast will make rougeN™ available to client labs as well as distribution partners in Europe, Middle East & Africa.
“Large-scale immune response testing helps understand the dynamics of the pandemic, and evolve more effective responses, particularly in the context of the proliferation of variants. Among other benefits, monitoring antibody levels helps determine vaccine durability, adapt vaccination strategies, and allows individuals to enjoy the benefits of increased social activity as social restrictions ease. Those who are not immune may opt to be more cautious, or be allowed an additional vaccine shot, subject to local regulations,” said Cecile Goulet, Chief Clinical Innovation Officer at Futurecast.
Yves Alavo, Founder & CEO of Futurecast adds: “This strategic partnership to lead the rollout of the rougeN™ test across these markets fully supports our vision to power health surveillance by making the most effective rapid screening innovations available to healthcare providers and individuals alike. While the rougeN™ test is already CE-certified it is currently under review by UK Department of Health & Social Care”.
About Futurecast Ltd
We are accelerating the advent of a decentralised and democratised healthcare ecosystem by simplifying access to innovation in care and empowering healthcare and non-healthcare operators. As an unconventional care company, our vision is to become the largest contributor to the state of preparedness of the world against health threats.
About RougeN Diagnostics Inc.
We are an innovative, USA-based biotech company specialised in rapid tests for emerging infectious diseases - and sold worldwide. Through innovative research and collaboration with public health institutions, governments and medical researchers, RougeN Diagnostics provides mission-critical testing for patients and healthcare providers. Our lab partner operates in a fully HIPAA compliant environment.